Capro: Q1 Sales Up but Operating Loss Continues, Delisting Risk and Litigation

Revenue 7.4B KRW (+382% YoY), operating loss 3.4B KRW, net loss 6.5B KRW → continued financial deterioration
Post-workout debt restructuring: debt-to-equity swap, repayment moratorium until 2028, interest rate reduction (secured 2.80%, unsecured 1.00%)
Delisting risk: Korea Exchange decided delisting, company filed injunction, stock trading remains suspended
Litigation: 1 lawsuit over personnel appointment (won in first trial, appeal ongoing), 2 criminal investigations pending
Dividends: none for past 5 years
Business shift: caprolactam production discontinued, transitioning to hydrogen and sulfuric acid sales (driver of revenue growth)
No shareholder return plans (no treasury share buyback or cancellation)